Global Surge in Metabolic Liver Disease: A Looming Health Crisis

A recent study published in the *Lancet Gastroenterology & Hepatology* journal indicates that metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is set to affect 1.8 billion people worldwide by 2050. This represents a significant increase from the current estimate of 1.3 billion individuals affected, marking a 143% rise over the past three decades. The condition, which currently impacts approximately 16% of the global population, is primarily driven by rising obesity rates and elevated blood sugar levels.

The Guardian

The study, conducted by the Institute for Health Metrics and Evaluation at the University of Washington, reveals that MASLD's prevalence has escalated from about 500 million cases in 1990 to 1.3 billion in 2023. Projections suggest a further increase of 42% by 2050. The global prevalence rate has reached 14,429 cases per 100,000 people, reflecting a 29% increase since 1990. Notably, MASLD is more prevalent among men and older adults, particularly those aged 80 to 84. However, the highest number of cases is found in younger demographics, specifically men aged 35 to 39 and women aged 55 to 59.

The Guardian

The study highlights significant regional disparities in MASLD prevalence. North Africa and the Middle East report disproportionately higher rates compared to other regions. In the UK, the prevalence increased by 33% from 1990 to 2023, the largest rise in Western Europe. Australia and the United States also saw increases of 30% and 22%, respectively. Despite the growing number of cases, the overall health impact, measured in years lost due to illness or death, has remained stable.

The Guardian

The findings underscore the urgent need for public health interventions. While advances in treatment and care have allowed individuals to live longer and healthier lives, the rising incidence of MASLD poses a risk for serious complications, including liver cirrhosis and cancer. The condition often goes unnoticed, as it typically does not present symptoms until later stages. Common symptoms include fatigue, general malaise, and abdominal discomfort.

The Guardian

The authors of the study emphasize the importance of recognizing MASLD as a global health priority. They advocate for the development of policies, awareness campaigns, and interventions aimed at mitigating its impact and preventing future complications. The study's findings call for increased public awareness and proactive measures to address the lifestyle factors contributing to the disease.

The Guardian

Despite the alarming projections, some experts argue that the increase in MASLD cases primarily reflects improved detection and awareness rather than a true rise in disease severity. They suggest that many individuals diagnosed with MASLD are in the early stages of the disease, where effective lifestyle interventions can lead to better health outcomes.

The Guardian

• “Its authors said the findings highlighted that MASLD was increasingly affecting younger adults, amid worsening health and lifestyles.” — Institute for Health Metrics and Evaluation

The Guardian

The study's conclusions prompt a reevaluation of public health strategies to address the growing burden of MASLD and its associated health risks.

The Guardian